A multifaceted approach targeting NK cells for better treatment of cancer: Focus on hematological malignancies

Blood Research

Volumn 50, Issue 4, 2015, Pages 189-191

  Kim, Hun Sik ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ELOTUZUMAB; INTERLEUKIN 15; INTERLEUKIN 21; LENALIDOMIDE; POMALIDOMIDE; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOIMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL ACTIVATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE MYELOMA; NATURAL KILLER CELL;

EID: 84951051690     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2015.50.4.189     Document Type: Article

References (10)

1. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S.Controlling natural killer cell responses: integration of signals foractivation and inhibition. Annu Rev Immunol 2013;31:227-58.
2. Rezvani K, Rouce RH. The application of natural killer cellimmunotherapy for the treatment of cancer. Front Immunol2015;6:578.
3. Chouaib S, Pittari G, Nanbakhsh A, et al. Improving the outcomeof leukemia by natural killer cell-based immunotherapeuticstrategies. Front Immunol 2014;5:95.
4. Watzl C. How to trigger a killer: modulation of natural killer cellreactivity on many levels. Adv Immunol 2014;124:137-70.
5. Cerboni C, Fionda C, Soriani A, et al. The DNA damage response:A common pathway in the regulation of nkg2d and dnam-1ligand expression in normal, infected, and cancer cells. FrontImmunol 2014;4:508.
6. Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S. Revvingup natural killer cells and cytokine-induced killer cells againsthematological malignancies. Front Immunol 2015;6:230.
7. Chretien AS, Le Roy A, Vey N, et al. Cancer-induced alterationsof NK-mediated target recognition: Current and investigationalpharmacological strategies aiming at restoring NK-mediatedanti-tumor activity. Front Immunol 2014;5:122.
8. Kwon HJ, Kwon SJ, Lee H, et al. NK cell function triggered bymultiple activating receptors is negatively regulated by glycogensynthase kinase-3ß. Cell Signal 2015;27:1731-41.
9. Mentlik James A, Cohen AD, Campbell KS. Combinationimmune therapies to enhance anti-tumor responses by NK cells.Front Immunol 2013;4:481.
10. Childs RW, Berg M. Bringing natural killer cells to the clinic: exvivo manipulation. Hematology Am Soc Hematol Educ Program2013;2013:234-46.